June 25, 2007: The Worcester Foundation for Biomedical Research (WFBR) of the University of Massachusetts Medical School presented two Gregory Pincus Medals — named for the WFBR co-founder and pioneer in reproductive biology — to scientists Dr. V. Craig Jordan and Dr. Angela Hartley Brodie. Renowned around the world for their innovative research into cancer treatments, Drs. Jordan and Brodie spent a formative segment of their early professional careers in the labs of what was then the Worcester Foundation for Experimental Biology.
Dr. Jordan has received international acclaim for his research into the anti-estrogen effects of Tamoxifen, hailed as one of the most significant therapies in the last 20 years for the treatment of breast cancer. Following receipt of his Ph.D. from the University of Leeds, Jordan spent two years at the Worcester Foundation for Experimental Biology, completing early investigations into the effects of Tamoxifen. Notably, he determined the compound could prevent the development of rat mammary cancer and work as an antitumor agent if given for long periods of time.
Jordan is currently the vice president and research director for Medical Sciences and the Alfred G. Knudson Chair for Cancer Research at the Fox Chase Cancer Center in Philadelphia, Pa.
Dr. Brodie is a professor of pharmacology and experimental therapeutics at the University of Maryland School of Medicine where she is also a member of the Marlene and Stewart Greenebaum Cancer Center. She is recognized for discovering and developing a new class of drugs called aromatase inhibitors. These drugs help to prevent recurrence of breast cancer in postmenopausal women by reducing the level of the hormone estrogen produced by the body, thereby cutting off the fuel that promotes the growth of cancer cells. The drugs also are used to treat postmenopausal women whose breast cancer has spread to other parts of the body.